Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06520319
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-21
Brief Title:
Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PETCT in Patients With Medullary Thyroid Carcinoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PETCT in Patients With Medullary Thyroid Carcinoma a Prospective Study
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cholecystokinin-2 CCK2 receptor is overexpressed in more than 90 of MTC cases and preclinical studies have shown that 68Ga-MGS5 targeting CCK2 has good stability in vivo and is promising for diagnosis and staging of MTC This prospective study will compare the diagnostic effects of 68Ga-MGS5 and 68Ga-DOTATATE on MTC primary foci lymph node metastasis and distant metastasis and explore the effect of 68Ga-MGS5 PETCT on the clinical staging TNM staging of MTC
Detailed Description:
This study was planned to enroll 20 patients with suspected MTC and MTC recurrence who attended the First Hospital of Fujian Medical University from June 2023 onwards Each patient completed PETCT examination within 1 week one 68Ga-DOTATATE PETCT whole-body examination and two 68Ga-MGS5 PETCT whole-body examinations 1 hour and 2 hours after injection respectively CCK2 immunohistochemical staining and expression scoring of primary foci and lymph node metastases were also performed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None